- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Financing & Capital Markets, Strategy & Corporate Development
An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed...
- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Strategy & Corporate Development